Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Hepatology

Topics

Medicine

Epidemiology

Internal Medicine

Gastroenterology

Hepatology

Show all topics

DOI

10.1002/hep.28467

License

CC-BY-NC-ND

Other Formats

PDF